Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response

BACKGROUND: HCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12 weeks as part of a 24- or 48-week combination regimen with PR is approved for the treatment of chronic HCV GT4 infection. Primary study objectives were assessment of efficacy and safety of simeprevir plu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:PLoS One
Asıl Yazarlar: Asselah, Tarik, Moreno, Christophe, Sarrazin, Christoph, Gschwantler, Michael, Foster, Graham R., Craxí, Antonio, Buggisch, Peter, Sanai, Faisal, Bicer, Ceyhun, Lenz, Oliver, Van Dooren, Gino, Nalpas, Catherine, Lonjon-Domanec, Isabelle, Schlag, Michael, Buti, Maria
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2017
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5215882/
https://ncbi.nlm.nih.gov/pubmed/28056030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0168713
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller